About — M Co., Ltd.

The Founder’s Vision

Our company was established in Tokyo, Japan in June 2021.

Why did I, a graduate student at Johns Hopkins University for more than 30 years and a professor of radiology at Johns Hopkins University living in the U.S., decide to establish a new company in Japan?

The impetus came from discussions with a Japanese medical institution that was a pioneer in the use of MRI/CT in Japan, particularly in human health care.

Almost all of the MRI/CT medical imaging data that exists in the world is data from people who have become ill.

On the other hand, Japanese medical institutions had more than 10,000 people's progress imaging data and medical checkup data for healthy people for more than 10 years, which is unparalleled in the world.

By combining this valuable medical image data with artificial intelligence analysis, which has advanced dramatically over the past several years, we believe that we can not only analyze the current status of medical examiners, but also make inferences about their future conditions.

Specifically, as the first step, we will develop brain-related analysis software by the end of FY2021 to suggest the possibility of dementia, which is said to affect 1/4 of the aging Japanese population, and to analyze cerebrovascular and tumor-related conditions. Thereafter, we are considering the development of analysis software related to cardiopulmonary, muscles, bones, and other parts of the body.

We hope to utilize the extremely valuable and rare data that existed only in Japan, and ultimately target not only Japan, but also Europe and the United States, where MRI/CT is advanced, as well as China and other emerging markets, where the market has been expanding rapidly in recent years. We hope to spread the use of medical software developed in Japan based on artificial intelligence and medical image data. Through this, we aim to provide support to as many people as possible in the form of "analysis and countermeasures" for serious illnesses such as dementia.

The Founder, Susumu Mori

Our Missions

Update Dementia Care with the Power of Medical Image Analysis

1. Manage brain health before symptoms appear

The best defense against lifestyle-related diseases is daily health management to prevent illness. The first step toward this is to know one's own health.
We, through MVision health, supports the monitoring of brain health from the stage of unwellness.

2. Detect and intervene in dementia early

With the gradual increase of dementia in seniors, we are beginning to see that its early diagnosis is the key to a better prognosis. Diagnosis and prognosis of dementia cannot be made by brain MRI alone. However, it is known that brain atrophy and vascular lesions begin to progress 5-10 years before cognitive decline.
Through the MVision series, we aim to maximize the information contained in brain MRI to support early diagnosis and more accurate prognosis of dementia. We will capture leading indicators of cognitive decline by understanding data over time and select the recipients of therapeutic agents that need to be administered in the very early stages of the disease.

3. Develop products to support diagnosis and treatment of dementia based on big data analysis of the brain

Through the MVision series, we will actively support joint research with academia and contribute to the development of dementia prevention, diagnosis, and treatment. Supporting the above three supports is the huge brain-doctoring data that exists only in Japan. Our goal is to elucidate the process leading from age-related changes in the brain to dementia based on analysis of past brain dock data, and to connect the future data of individual examinees to dementia prevention and early diagnosis.

4. Unleash the potential of radiologists, dementia specialists

We will leave to machines (MVision will be responsible for this) those things that are more accurate and faster than machines, such as measuring volume and atrophy from images. Physicians will be able to devote more of their resources to comprehensive communication with dementia patients.